Novartis Privacy Hub

Welcome to the Novartis Privacy Hub.

On this site you can read our privacy notices, get in contact with us, and learn about our approach and commitment to data privacy.

Everyone expects their personal information to remain confidential. This includes anything that can identify them - name, work and home address, family information, employment or financial details, or more sensitive health information. We strongly condemn the disclosure of any information that could lead to any form of discrimination, as well as the use of identifiable genetic data without informed consent.

We seek to adhere to all privacy laws and enforce clear Novartis Data Privacy Principles, which also apply to genetic data. Our data privacy program includes a global organization and infrastructure as well as procedures and training to support local activities and help our efforts to ensure compliance. In addition, the Novartis Binding Corporate Rules are a system of principles, rules, and tools designed to ensure effective levels of data protection, in particular relating to transfers of personal information outside Europe and Switzerland.

We invite you to carefully read our privacy notices, which set out how we process your personal information and explain your rights and our obligations.

These privacy notices address your interactions with global Novartis entities, including Novartis International AG and Novartis Pharma AG. For country-specific privacy notices, please visit the relevant local site.


Website Privacy Policy

This serves as a notice for people that visit this website and other global Novartis websites.


General Privacy Notice for Business Partners

This notice is for healthcare professionals we create or maintain a relationship with, our customers or prospective customers who are natural persons (such as self-employed pharmacists), and representatives or contact persons of our customers or prospective customers who are legal entities (such as wholesale pharmacists).


General Privacy Notice for Third Parties

This notice is for our suppliers and service providers who are natural persons (such as self-employed persons), representatives or contact persons of our suppliers and service providers who are legal entities, and visitors to one of our facilities.


General Privacy Notice for External Stakeholders

This notice is for our external stakeholders, including institutional decision-makers, civil servants, politicians and political decision-makers, journalists and media, patient associations, industry affiliations, and influencers.


Privacy Notice for Pharmacovigilance, Medical Information, and Product Quality Complaints

This notice is for people that report adverse events, people that provide safety information concerning our products and submit product quality complaints, and people that are the subject of adverse events and product quality complaints.


Data Privacy Notice for Job Prospects and Candidates (PDF 3 MB)

This notice is for job applicants and candidates for roles within Novartis Group.


General Privacy Notice for Clinical Trial Site Personnel

This notice is for Clinical investigators (principal investigators, sub-investigators or co-investigators) and other site staff such as nurses, pharmacists or technicians, whose Personal Data may be processed in the course of the clinical trials and studies sponsored or organized by Novartis.


Twitter community guidelines, Facebook community guidelines, Instagram community guidelines, LinkedIn community guidelines, Youtube community guidelines

These guidelines are for people that visit our social media sites and pages.

If you wish to contact us regarding how we use your personal information, please email us at [email protected]. You may also write to us at Novartis Pharma AG, Global Privacy Office, Fabrikstrasse 18, 4056 Basel, Switzerland. In order to facilitate the most efficient answer, please provide a description of your relationship with us and the information you would like to receive from us.

If you wish to exercise your data privacy rights, under the conditions and within the limits set forth in the law, please click here.

Some states (including but not limited to California, Nevada and Texas), have state specific rights for their residents. Click here to learn more about those state specific rights.

Novartis is committed to use Personal Information ethically and responsibly. To complement the Novartis Policy on Ethical Use of Data & Technology, Novartis has adopted BCR. BCR are a set of principles governing the international transfer of Personal Information within the Novartis group, from the European Economic Area, Switzerland and the UK, to other Novartis entities located elsewhere in the world. Click here to learn more about the Novartis BCR.

Novartis quarterly financial results

Q3 2025 results - Tuesday, October 28, 2025

Press release: English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB)

Interim financial report (PDF 0.4 MB)

Watch the webcast

Download the interactive presentation (PDF 5.6 MB)

Download the podcast (MP3 31 MB)
 

Key figures1Q3 2025
(USD m)
Q3 2024
(USD m)
% change
(USD/cc)
Net sales13,90912,8238 (cc: 7)
Operating income4,5013,62724 (cc: 27)
Net income3,9303,18523 (cc: 25)
EPS (USD)2.041.5829 (cc: 31)
Free cash flow6,2175,9654

Core
   
Operating income5,4605,1456 (cc: 7)
Net income4,3304,1335 (cc: 6)
EPS (USD)2.252.069 (cc: 10)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 42 of the Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

 

Q2 2025 results - Thursday, July 17, 2025

Press release: English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB)

Interim financial report (PDF 0.4 MB)


Quarterly impact and sustainability update (ESG):
Novartis Q2 2025 impact and sustainability update (PDF 0.8 MB)


Watch the webcast

Download the interactive presentation (PDF 4.6 MB)

Download the podcast (MP3 31 MB)

 

Key figures1Q2 2025
(USD m)
Q2 2024
(USD m)
% change
(USD/cc)
Net sales14,05412,51212 (cc: 11)
Operating income4,8644,01421 (cc: 25)
Net income4,0243,24624 (cc: 26)
EPS (USD)2.071.6029 (cc: 32)
Free cash flow6,3334,61537

Core
   
Operating income5,9254,95320 (cc: 21)
Net income4,7104,00818 (cc: 19)
EPS (USD)2.421.9723 (cc: 24)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 40 of the Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

Q1 2025 results - Tuesday, April 29, 2025

Press release: English (PDF 0.3 MB) | Deutsch (PDF 0.3 MB)

Interim financial report (PDF 0.3 MB)


Quarterly impact and sustainability update (ESG):
Novartis Q1 2025 impact and sustainability update (PDF 0.9 MB)


Watch the webcast

Download the interactive presentation (PDF 3.7 MB)

Download the podcast (MP3 32 MB)

Download 2025 epidemiology data (PDF 2.0 MB)
 

Key figures1Q1 2025
(USD m)
Q1 2024
(USD m)
% change
(USD/cc)
Net sales13,23311,82912 (cc: 15)
Operating income4,6633,37338 (cc: 44)
Net income3,6092,68834 (cc: 37)
EPS (USD)1.831.3140 (cc: 42)
Free cash flow3,3912,03866

Core
   
Operating income5,5754,53723 (cc: 27)
Net income4,4823,68122 (cc: 26)
EPS (USD)2.281.8027 (cc: 31)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 31 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

 

Annual results and Q4 2024
Friday, January 31, 2025

Press release: English (PDF 0.4 MB) | Deutsch (PDF 0.4 MB)

Condensed financial report (PDF 0.5 MB)


Quarterly impact and sustainability update (ESG):
Novartis Q4 2024 impact and sustainability update (PDF 1.0 MB)


Watch the webcast

Download the presentation (PDF 4.7 MB)

Read the transcript

Download the podcast (MP3 30 MB) 
 

Key figures1

Continuing operations2

 Q4 2024
(USD m)
Q4 2023
(USD m)
% change
(USD/cc)
Net sales13,15311,42315 (cc: 16)
Operating income3,5302,58237 (cc: 39)
Net income2,8202,6387 (cc: 6)
EPS (USD)1.421.2910 (cc: 10)
Free cash flow3,6352,14170

Core
   
Operating income4,8593,82127 (cc: 29)
Net income3,9333,12626 (cc: 29)
EPS (USD)1.981.5329 (cc: 33)
  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 47 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
  2. As defined on page 35 of the Condensed Financial Report, Continuing operations include the retained business activities of Novartis, comprising the innovative medicines business and the continuing corporate activities, and Discontinued operations include operational results from the Sandoz business.

2024 quarterly results

Q3 2024 press release (PDF 0.4 MB)

Q3 2024 financial report (PDF 0.6 MB)

Q2 2024 press release (PDF 0.5 MB)

Q2 2024 financial report (PDF 0.5 MB)

Q1 2024 press release (PDF 0.4 MB)

Q1 2024 financial report (PDF 0.5 MB)

2023 quarterly results

Q4 2023 press release (PDF 0.3 MB)

Q4 2023 financial report (PDF 0.6 MB)

Q3 2023 press release (PDF 0.4 MB)

Q3 2023 financial report (PDF 0.6 MB)

Q2 2023 press release (PDF 0.3 MB)

Q2 2023 financial report (PDF 0.5 MB)

Q1 2023 press release (PDF 0.3 MB)

Q1 2023 financial report (PDF 0.3 MB)

2022 quarterly results

Q4 2022 press release (PDF 0.3 MB)

Q4 2022 financial report (PDF 0.5 MB)

Q3 2022 press release (PDF 0.3 MB)

Q3 2022 financial report (PDF 0.5 MB)

Q2 2022 press release (PDF 0.2 MB)

Q2 2022 financial report (PDF 0.5 MB)

Q1 2022 press release (PDF 0.2 MB)

Q1 2022 financial report (PDF 0.4 MB)

2021 quarterly results

Q4 2021 press release (PDF 0.3 MB)

Q4 2021 financial report (PDF 0.5 MB)

Reconciliation of 2021 results excluding Roche investment impacts (PDF 0.5 MB)

Q3 2021 press release (PDF 0.3 MB)

Q3 2021 financial report (PDF 0.5 MB)

Q2 2021 press release (PDF 0.4 MB)

Q2 2021 financial report (PDF 0.5 MB)

Q1 2021 press release (PDF 0.2 MB)

Q1 2021 financial report (PDF 0.4 MB)

2020 quarterly results

Q4 2020 press release (PDF 0.2 MB)

Q4 2020 financial report (PDF 0.9 MB)

Q3 2020 press release (PDF 0.2 MB)

Q3 2020 financial report (PDF 0.8 MB)

Q2 2020 press release (PDF 0.1 MB)

Q2 2020 financial report (PDF 0.8 MB)

Q1 2020 press release (PDF 0.2 MB)

Q1 2020 financial report (PDF 0.6 MB)